SPDR S&P Pharmaceuticals ETFXPH
XPH
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
86% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 14
10.63% more ownership
Funds ownership: 52.8% [Q3] → 63.42% (+10.63%) [Q4]
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
3% more capital invested
Capital invested by funds: $98.4M [Q3] → $101M (+$2.53M) [Q4]
0% more funds holding
Funds holding: 71 [Q3] → 71 (+0) [Q4]
52% less call options, than puts
Call options by funds: $813K | Put options by funds: $1.69M
Research analyst outlook
We haven’t received any recent analyst ratings for XPH.
Financial journalist opinion
Neutral
CNBC Television
3 weeks ago
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Negative
Market Watch
3 weeks ago
Trump teases targeted tariffs on overseas drug manufacturers
With the next set of White House–imposed tariffs just hours away from taking effect — including the attention-hogging 104% rate to be levied on products from China as they're imported into the U.S. — President Donald Trump indicated he intends to roll out more product-specific tariffs down the road.
Neutral
Seeking Alpha
2 months ago
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?
Positive
Zacks Investment Research
8 months ago
Pharma ETFs in Focus Post Solid Q2 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Neutral
Zacks Investment Research
9 months ago
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
The SPDR S&P Pharmaceuticals ETF (XPH) was launched on 06/19/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
Neutral
Zacks Investment Research
9 months ago
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund launched on 06/19/2006.
Neutral
ETF Trends
10 months ago
Finding Opportunity in Unloved Healthcare ETFs
Sometimes it feels like it's Nvidia's world and we all just live in it. Why bother with anything else?
Neutral
Zacks Investment Research
11 months ago
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund launched on 06/19/2006.
Positive
Zacks Investment Research
11 months ago
5 Beaten-Down Top-Ranked ETFs to Buy for a Turnaround
We have highlighted five ETFs from different zones that have plunged the most so far this year but have a solid Zacks ETF Rank.
Positive
Zacks Investment Research
11 months ago
A Look at Pharma ETFs Post Q1 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Charts implemented using Lightweight Charts™